leisure time -WSS

leisure time

author：comprehensive 2025-09-10 04:17:24 - browse：99

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Scientists unlock the key to scar

knowledge

WSS

How to address the problem of discarded donor organs

The United States is paying nearly triple for new Covid vaccines

Stop Congress from blocking public access to science

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Will an HIV vaccine ever be a reality?

WHO recommends second malaria vaccine

Wikipedia

leisure time

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Obesity now affects over 1 billion people worldwide, study finds

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why getting cancer drugs just got harder for rural patients

How to save PrEP access — and even expand it

CDC picks Alphabet's Verily for wasterwater surveillance contract

Anesthesiologist group: stop taking Ozempic before surgery

IVG is promising — but it won’t replace IVF quite yet

Moonlake's readout produced a cash windfall. Risks remain

Medical device lobby: We're tired of waiting on Medicare coverage

hotspot

The United States is paying nearly triple for new Covid vaccines

CRISPR base editing slashes cholesterol levels in monkeys

Will an HIV vaccine ever be a reality?

The Karikó problem: Lessons for funding basic research

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Medical device lobby: We're tired of waiting on Medicare coverage

Wikipedia

explore

knowledge

entertainment